Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis

Journal of Viral Hepatitis

Volumn 24, Issue 2, 2017, Pages 117-127

  Esmaeili, A ^a,d   Mirzazadeh, A ^b   Carter, G M ^c   Hajarizadeh, B ^e   Sacks, H S ^a   Page, K A ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Foundation for Integrative AIDS Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

females; hepatitis C; incidence; meta analysis; sex differences; systematic review

Indexed keywords

ARTICLE; CHINA; GEOGRAPHY; HEPATITIS C; HUMAN; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; PRIORITY JOURNAL; SEX DIFFERENCE; SEX RATIO; SYSTEMATIC REVIEW; UNITED STATES; COMPLICATION; DRUG USE; FEMALE; MALE; META ANALYSIS; SUBSTANCE ABUSE;

DRUG USERS; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; MALE; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84996572313     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12628     Document Type: Article

References (50)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45–S57.
2. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342.
4. Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide – filling the gaps. J Viral Hepat. 2015;22(Suppl 1):1–5.
5. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081–8.
6. Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology. 2000;31:756–762.
7. Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One. 2014;9:e97596.
8. Evans JL, Hahn JA, Page-Shafer K, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003;80:137–146.
9. Iversen J, Wand H, Topp L, Kaldor J, Maher L. Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am J Public Health. 2013;103:1436–1444.
10. Morris MD, Bates A, Andrew E, Hahn J, Page K, Maher L. More than just someone to inject drugs with: injecting within primary injection partnerships. Drug Alcohol Depend. 2015;156:275–281.
11. Morris MD, Evans J, Montgomery M, et al. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA. PLoS One. 2014;9:e109282.
12. Tracy D, Hahn JA, Fuller Lewis C, et al. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. BMJ Open. 2014;4:e004988.
13. Folch C, Casabona J, Espelt A, et al. Gender differences in HIV risk behaviours among intravenous drug users in Catalonia, Spain. Gac Sanit. 2013;27:338–343.
14. Hurtado Navarro I, Alastrue I, Del Amo J, et al. Differences between women and men in serial HIV prevalence and incidence trends. Eur J Epidemiol. 2008;23:435–440.
15. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 1998;317:433–437.
16. Viitanen P, Vartiainen H, Aarnio J, et al. Hepatitis A, B, C and HIV infections among Finnish female prisoners–young females a risk group. J Infect. 2011;62:59–66.
17. CDC. Surveillance for Viral Hepatitis – United States, 2013. 2013: Division of Viral Hepatitis and National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
18. Duffell E. Hepatitis C surveillance in Europe –2013. In: European Centre for Disease Prevention and Control, Vol. 2015. Stockholm: ECDC; 2015.
19. Wu HX, Wu J, Wong T, et al. Enhanced surveillance of newly acquired hepatitis C virus infection in Canada, 1998 to 2004. Scand J Infect Dis. 2006;38:482–489.
20. Hagan H, Des Jarlais DC, Stern R, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007;18:341–351.
21. Onofrey S, Aneja J, Haney GA, et al. Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review. Ann Intern Med. 2015;163:254–261.
22. Carlson MD, Morrison RS. Study design, precision, and validity in observational studies. J Palliat Med. 2009;12:77–82.
23. Micallef JM, Macdonald V, Jauncey M, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat. 2007;14:413–418.
24. Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006;101:1499–1508.
25. Broers B, Junet C, Bourquin M, Deglon JJ, Perrin L, Hirschel B. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS. 1998;12:2059–2066.
26. Roy E, Alary M, Morissette C, et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS. 2007;18:23–27.
27. Ruan Y, Qin G, Yin L, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS. 2007;21(Suppl 8):S39–S46.
28. van de Laar TJ, Molenkamp R, van den Berg C, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol. 2009;51:667–674.
29. Stern RK, Hagan H, Lelutiu-Weinberger C, et al. The HCV Synthesis Project: scope, methodology, and preliminary results. BMC Med Res Methodol. 2008;8:62.
30. Wells G, Shea B, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa: Ottawa Hospital Research Institute; 2014
31. Altman DG, Bland JM. How to obtain the confidence interval from a P value. BMJ. 2011;343:d2090.
32. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204:74–83.
33. Stein MD, Herman DS, Anderson BJ. A trial to reduce hepatitis C seroincidence in drug users. J Addict Dis. 2009;28:389–398.
34. Morris MDSS, Bruneau J, Maher L, et al, on behalf of the InC3 Collaborative. Geographic differences in temporal incidence trends of hepatitis C virus (HCV) infection among people who inject drugs: the InC3 Collaborative (Under editorial review). 2016.
35. Gilchrist G, Torrens M. Reducing hepatitis C sexual and drug taking risk behaviours among female drug users in Europe (REDUCE). The Parc de Salut Mar, Barcelona, Spain, 2010-2013.
36. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–583.
37. Puri N, DeBeck K, Feng C, Kerr T, Rieb L, Wood E. Gender influences on hepatitis C incidence among street youth in a Canadian setting. J Adolesc Health. 2014;55:830–834.
38. Cai L, Gao C, Tang S, et al. Sex-specific association of estrogen receptor 2 polymorphisms with hepatitis C virus infection outcomes in a high-risk Chinese Han population. Infect Genet Evol. 2014;28:118–124.
39. Grebely J, Page K, Sacks-Davis R, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59:109–120.
40. Sacks-Davis R, Grebely J, Dore GJ, et al. Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection-the InC3 Study. J Infect Dis. 2015;212:1407–1419.
41. Livingston SE, Townshend-Bulson LJ, Bruden DJ, et al. Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C. Int J Circumpolar Health. 2016;75:30696.
42. Thornton K, Deming P, Manch RA, et al. Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment Hepatol Int. 2016;10:624–631.
43. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200:1216–1226.
44. Vickerman P, Grebely J, Dore GJ, et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis. 2012;205:1342–1350.
45. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91:102–123.
46. Razani N, Mohraz M, Kheirandish P, et al. HIV risk behavior among injection drug users in Tehran, Iran. Addiction. 2007;102:1472–1482.
47. Simmonds L, Coomber R. Injecting drug users: a stigmatised and stigmatising population. Int J Drug Policy. 2009;20:121–130.
48. Page K, Tsui J, Maher L, et al. Biomedical HIV prevention including pre-exposure prophylaxis and opiate agonist therapy for women who inject drugs: state of research and future directions. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S169–S175.
49. MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25:34–52.
50. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012.